FDA Clocks Review Time for LOQTORZI Patent Boost
Published Date: 5/30/2025
Notice
Summary
The FDA has set the official review period for LOQTORZI, a new medicine, so its patent can be extended. This helps the company behind LOQTORZI get extra time to protect their invention before others can copy it. This means the drug maker could have more exclusive sales time, which might impact when generic versions can appear.
Analyzed Economic Effects
1 provisions identified: 0 benefits, 1 costs, 0 mixed.
Patent Extension May Delay Generics
The FDA set the official regulatory review period for LOQTORZI so the drugmaker can apply to extend a patent on this human biological product. That extension could give the company extra exclusive sales time for LOQTORZI and might delay when generic or biosimilar versions can appear. If you buy or pay for LOQTORZI, that could mean waiting longer for cheaper alternatives.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-20663, Agency Information Collection Activities; Proposed Collection; Comment Request; Channels of Trade Policy for Commodities With Residues of Pesticide Chemicals, for Which Tolerances Have Been Revoked, Suspended, or Modified by the Environmental Protection Agency Pursuant to Dietary Risk Considerations
The FDA wants your thoughts on how they collect info about food products that might have tiny amounts of banned or changed pesticides. This affects farmers, food sellers, and anyone handling these foods, making sure safety rules keep up with new pesticide limits. You’ve got until December 7, 2026, to share your views—no cost, just your voice!
Previous / Next Documents
Previous: 2025-09637, Constellation Energy Generation, LLC; Peach Bottom Atomic Power Station Units 2 and 3; Draft Supplement to Environmental Impact Statement
The NRC is asking for public feedback on extending the Peach Bottom Atomic Power Station’s license to keep running Units 2 and 3 for 20 more years. This affects people near Peach Bottom Township, PA, and looks at environmental impacts and possible alternatives. The process includes chances to speak up and could influence energy plans and local safety for decades.
Next: 2025-09756, Holtec Decommissioning International, LLC and Holtec Palisades, LLC; Palisades Nuclear Plant; Environmental Assessment and Finding of No Significant Impact
The Palisades Nuclear Plant is getting a green light to keep running and refuel, thanks to Holtec and some federal support. This means the plant can keep providing power safely without big environmental worries. The government’s loan guarantee helps make sure the plant stays up and running smoothly and on time.